SG11202004115WA - Edasalonexent dosing regimen for treating muscular dystrophy - Google Patents

Edasalonexent dosing regimen for treating muscular dystrophy

Info

Publication number
SG11202004115WA
SG11202004115WA SG11202004115WA SG11202004115WA SG11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA
Authority
SG
Singapore
Prior art keywords
edasalonexent
muscular dystrophy
dosing regimen
treating muscular
treating
Prior art date
Application number
SG11202004115WA
Inventor
Andrew Nichols
Michael Perlman
Original Assignee
Catabasis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catabasis Pharmaceuticals Inc filed Critical Catabasis Pharmaceuticals Inc
Publication of SG11202004115WA publication Critical patent/SG11202004115WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11202004115WA 2017-11-06 2018-11-05 Edasalonexent dosing regimen for treating muscular dystrophy SG11202004115WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581981P 2017-11-06 2017-11-06
PCT/US2018/059283 WO2019090271A1 (en) 2017-11-06 2018-11-05 Edasalonexent dosing regimen for treating muscular dystrophy

Publications (1)

Publication Number Publication Date
SG11202004115WA true SG11202004115WA (en) 2020-06-29

Family

ID=66332350

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004115WA SG11202004115WA (en) 2017-11-06 2018-11-05 Edasalonexent dosing regimen for treating muscular dystrophy

Country Status (16)

Country Link
US (1) US20210023029A1 (en)
EP (1) EP3706730A4 (en)
JP (1) JP2021502328A (en)
KR (1) KR20200084877A (en)
CN (1) CN111315372A (en)
AU (1) AU2018359969A1 (en)
BR (1) BR112020009020A2 (en)
CA (1) CA3078727A1 (en)
CL (1) CL2020001180A1 (en)
CO (1) CO2020006395A2 (en)
IL (1) IL274375A (en)
MX (1) MX2020004659A (en)
PH (1) PH12020550526A1 (en)
RU (1) RU2020118258A (en)
SG (1) SG11202004115WA (en)
WO (1) WO2019090271A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020191087A1 (en) * 2019-03-18 2020-09-24 Ptc Therapeutics, Inc. Therapeutic combinations for use in treating a muscular dystrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2315740T1 (en) * 2008-07-08 2018-03-30 Catabasis Pharmaceuticals, Inc. Fatty acid acetylated salicylates and their uses
PT2519230T (en) * 2009-12-31 2019-01-18 Marius Pharmaceuticals Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
NZ601698A (en) * 2010-01-08 2015-04-24 Catabasis Pharmaceuticals Inc Fatty acid fumarate derivatives and their uses

Also Published As

Publication number Publication date
KR20200084877A (en) 2020-07-13
BR112020009020A2 (en) 2020-10-27
RU2020118258A (en) 2021-12-08
EP3706730A4 (en) 2021-08-11
WO2019090271A1 (en) 2019-05-09
IL274375A (en) 2020-06-30
CA3078727A1 (en) 2019-05-09
CL2020001180A1 (en) 2020-09-25
CO2020006395A2 (en) 2020-06-09
JP2021502328A (en) 2021-01-28
CN111315372A (en) 2020-06-19
EP3706730A1 (en) 2020-09-16
US20210023029A1 (en) 2021-01-28
AU2018359969A1 (en) 2020-05-14
PH12020550526A1 (en) 2021-05-10
MX2020004659A (en) 2020-10-14

Similar Documents

Publication Publication Date Title
HK1258823A1 (en) Methods for treating muscular dystrophy
GB201713653D0 (en) Dosage regimen
SI3347054T1 (en) Dosing regimens for anti-tf-antibody drug-conjugates
EP3389589C0 (en) Dosing device
HK1259491A1 (en) Dosing regimens
IL272791A (en) Methods for treating muscular dystrophy
HRP20181572T1 (en) Fgf-18 compound dosing regimen
IL273419A (en) Dosing regimen of siponimod
IL265762A (en) Dosing regimen of avelumab for the treatment of cancer
GB2540877B (en) A dosing apparatus
IL273382A (en) Dosing regimen of siponimod
IL274375A (en) Edasalonexent dosing regimen for treating muscular dystrophy
HK1249912A1 (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
IL266255A (en) Novel dosage regimen
GB201720519D0 (en) Dosing regimen
GB201718106D0 (en) Dosing regimen
GB201718000D0 (en) Dosing regimen
GB201717694D0 (en) Dosing regimen
GB201609758D0 (en) Dosing Regimen
GB201617850D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
GB201611236D0 (en) Dosing tubes